Aurion Biotech, Inc. (AURN)
| Market Cap | n/a |
| Revenue (ttm) | 657,000 |
| Net Income (ttm) | -59.92M |
| Shares Out | n/a |
| EPS (ttm) | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | n/a |
| Previous Close | n/a |
| Day's Range | n/a |
| 52-Week Range | n/a |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About AURN
Aurion Biotech is a clinical-stage biotechnology company committed to developing and commercializing disease-modifying, regenerative therapies to restore vision to millions of patients worldwide. We are advancing a single administration, allogeneic cell therapy to treat vision loss due to corneal endothelial diseases. In Japan, our first-generation cell therapy product, HCEC-1, received regulatory and reimbursement approval, and launched commercially in September 2024 under the marketed name Vyznova. Our next-generation product candidate, AURN0... [Read more]
News
U.S. IPO Weekly Recap: IPO Calendar Slows Down With Small Listings
The calendar slowed down this past week, with only small listings in the US. There was one sizable filing this past week - AIRO Group Holdings. No IPOs are currently scheduled to list in the week ahea...
Aurion Biotech Pursues IPO For Cornea Disease Treatments
Aurion Biotech, Inc. aims to raise $100 million in an IPO to fund the development and commercialization of treatments for corneal diseases, including its lead candidate AURN001. The firm's lead produc...
Vision loss biotech Aurion Biotech files for a $100 million IPO
Aurion Biotech, a commercial-stage biotech developing regenerative cell therapies for eye diseases, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
Aurion Biotech IPO Registration Document (S-1)
Aurion Biotech has filed to go public with an IPO on the New York Stock Exchange (NYSE).